Dupixent® (dupilumab) phase 3 trial shows positive results in children 1 to 11 years of age with eosinophilic esophagitis

First and only investigational phase 3 trial to show positive results in these young children; results follow recent approval of dupixent in people with eosinophilic esophagitis aged 12 years and older who weigh at least 40 kilograms trial met its primary endpoint, with 68% of patients on higher dose dupixent and 58% on lower dose dupixent achieving histological disease remission at 16 weeks fifth pediatric pivotal trial across three type 2 inflammatory diseases to reinforce the well-established efficacy and safety profile of dupixent tarrytown, n.y. and paris , july 14, 2022 /prnewswire/ -- regeneron pharmaceuticals, inc. (nasdaq: regn) and sanofi today announced that a phase 3 trial assessing the investigational use of dupixent® (dupilumab) in children aged 1 to 11 years with eosinophilic esophagitis (eoe) met its primary endpoint of histological disease remission at 16 weeks with both higher and lower dose weight-tiered regimens.
REGN Ratings Summary
REGN Quant Ranking